VIVUS (VVUS) Trading Down 0%
VIVUS, Inc. (NASDAQ:VVUS) shares were down 0% during mid-day trading on Wednesday . The stock traded as low as $0.52 and last traded at $0.53. Approximately 914,620 shares were traded during mid-day trading, an increase of 41% from the average daily volume of 646,650 shares. The stock had previously closed at $0.53.
Several research analysts recently issued reports on VVUS shares. ValuEngine cut VIVUS from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut VIVUS from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th.
The firm has a market cap of $52.70, a P/E ratio of -1.76 and a beta of 0.57. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09.
Large investors have recently made changes to their positions in the stock. Creative Planning boosted its position in VIVUS by 1,691.3% during the 4th quarter. Creative Planning now owns 366,706 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 346,235 shares in the last quarter. Macquarie Group Ltd. bought a new stake in VIVUS during the 3rd quarter valued at $192,000. Northern Trust Corp boosted its position in VIVUS by 16.8% during the 2nd quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after acquiring an additional 39,473 shares in the last quarter. Russell Investments Group Ltd. boosted its position in VIVUS by 166.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 246,927 shares in the last quarter. Finally, OxFORD Asset Management LLP boosted its position in VIVUS by 14.0% during the 3rd quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock valued at $1,040,000 after acquiring an additional 129,871 shares in the last quarter. 24.92% of the stock is currently owned by institutional investors.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.